Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HEME-25 Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV in Consolidation After Definitive Therapy (The EPIC Study)

NCT07647432 is registered in ClinicalTrials.gov with University of Illinois at Chicago as lead sponsor.

NCT NCT07647432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07647432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HEME-25 Open-Label Feasibility Study of Elranatamab Utilized in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV in Consolidation After Definitive Therapy (The EPIC Study)
Lead sponsor
University of Illinois at Chicago
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
December 1, 2030
Enrollment
17 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

consolidation, hiv, plasmablastic lymphoma